Introduction {#sec1}
============

The outbreak of the coronavirus-2-related acute respiratory distress syndrome pandemic by late 2019 has had a particularly deep impact on cancer health care due to the inherent features of this high-risk group of patients.[@bib1] ^,^ [@bib2] Scientific reports from Asia, Europe, and North America have remarked on the difficulties to overcome to guarantee proper delivery of continuous oncologic treatment.[@bib3], [@bib4], [@bib5] Scarce data regarding the impact of COVID-19 on developing economies have been published to date.

Latin America constitutes a region where health care, especially oncology, has been chronically neglected.[@bib6] ^,^ [@bib7] The rapid development of the pandemic is currently showing the overall fragility and impaired response measures of regional public health policies and institutional capacities.[@bib8] Radiation therapy is an essential, nonelective service. Considering the region-wide existing deficit and centralized distribution of facilities, any threat to radiation therapy capacity in Latin America endangers patients' access to ideal treatment options.[@bib9] ^,^ [@bib10]

Knowing the current real impact of the COVID-19 pandemic on radiation therapy services across the region might yield insights for cancer control policy. Recently, an impact survey was distributed to radiation oncology practice leaders in the United States by the American Society for Radiation Oncology (ASTRO). This was also administered in Europe by the European Society for Radiation Oncology. With ASTRO's permission, we administered this survey across Latin America to assist in identifying the impact of COVID-19 on our region.

Methods and Materials {#sec2}
=====================

ASTRO's permission was obtained to distribute the COVID-19 Survey. Spanish translation was performed by 2 native-speaker radiation oncologists. The survey's content was uploaded to the REDCap online platform (Research Electronic Data Capture, Vanderbilt University, Tennessee) for data storage and analysis in both Spanish and English. National radiation therapy society presidents or key opinion leaders from Argentina, Aruba, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Mexico, Panama, Paraguay, Peru, Uruguay, and Venezuela were individually contacted. They were instructed to distribute the survey exclusively to department heads or directors. Only 1 answer from each center was accepted.

From May 6 to May 30, the answers were recorded. In total, 26 items between entries and questions were requested to be completed. Data were anonymized to display only the country of origin. The detailed survey in Spanish can be observed in [Appendix EA](#appsec1){ref-type="sec"}. Frequencies in absolute and percentage values for each field and corresponding median values when applicable were analyzed and displayed, matched with the formulated question in English.

Results {#sec3}
=======

Overall, 229 centers were contacted. Complete answers were obtained from a total of 115 surveys (50.2% response rate) and subsequently analyzed, with 85.2% in Spanish and 14.8% in English. Answers were recorded from Argentina (10.4%), Aruba (0.9%), Bolivia (1.7%), Brazil (17.4%), Chile (6.1%), Colombia (13.0%), Costa Rica (0.9%), Dominican Republic (2.6%), Ecuador (1.7%), El Salvador (0.9%), Mexico (26.1%), Panama (0.9%), Paraguay (0.9%), Peru (14.8%), and Venezuela (1.7%) ([Table 1](#tbl1){ref-type="table"} ). Practice financiers were found to be distributed between public (41.1%) and private (50.9%) sources. Other systems were also reported (8%). The median number of radiation oncologists per center was 4 (range, 1-27) and radiation therapists per center was 9 (1-100). Among all participating centers, 87.8% treated 2000 or fewer new patients in 2019, with a median of 600 (24-6200).Table 1Participant countriesCountries (N = 115 responses)n%Argentina1210.4Aruba10.9Bolivia21.7Brasil2014.7Chile76.7Colombia1513.0Costa Rica10.9Ecuador21.7El Salvador10.9Mexico3026.1Panamá10.9Paraguay10.9Perú1714.8República Dominicana32.6Venezuela21.7

Overall, over 97% of practices continued to provide radiation services during the pandemic. Only 2.6% (n = 3) of the responding Latin American centers are currently closed due to the pandemic. Telemedicine was newly incorporated in 64.3% of facilities for on-treatment (29.6%) and posttreatment (34.8%) follow-up. Practices reported a median of 53 (1-490) patients under treatment; however, 80.9% reported a reduction in patient volume (median reduction, 8%; 1%-90%). The estimated revenue decrease was \>20% in 53% of answers, whereas 1.7% expected their revenue to increase.

Notably, primaries or sites by affected treatment delays are mostly early stage breast cancer (42.6%), low-grade gliomas (24.3%), low-risk prostate cancer (PC) (67%), intermediate-risk PC (41.7%), high-risk PC (13.9%), nonurgent palliative treatments (23.5%), and nonmalignant conditions (42.6%). Detailed locations and entities can be observed in [Table 2](#tbl2){ref-type="table"} .Table 2What disease sites/treatments are currently being delayed? (N = 115 participants)ParticipantsN%**Early stage breast**[∗](#tbl2fnlowast){ref-type="table-fn"}**4942.6**Locally advanced breast43.5Small cell lung32.6NSCLC early stage SBRT32.6NSCLC locally advanced21.7Early stage definitive HN43.5Locally advanced definitive HN21.7Post-operative adjuvant HN87.0**CNS**---**low grade glioma**[∗](#tbl2fnlowast){ref-type="table-fn"}**2824.3**CNS---high-grade glioma21.7CNS---GBM32.6GI---Esophageal/gastric32.6GI---pancreas10.9GI---liver54.3GI---rectal21.7GI---anal21.7**Prostate---low risk**[∗](#tbl2fnlowast){ref-type="table-fn"}**7767.0Prostate---intermediate risk**[∗](#tbl2fnlowast){ref-type="table-fn"}**4841.7Prostate---high-risk**[∗](#tbl2fnlowast){ref-type="table-fn"}**1613.9**Bladder21.7Sarcoma21.7GYN---cervical43.5GYN---uterine97.8GYN---vagina/vulva21.7**Palliative non-emergent**[∗](#tbl2fnlowast){ref-type="table-fn"}**2723.5**Palliative emergent10.9Oligometastatic SBRT87.0Cutaneous: melanoma65.2**Cutaneous: Non-melanoma**[∗](#tbl2fnlowast){ref-type="table-fn"}**1916.5Nonmalignant conditions**[∗](#tbl2fnlowast){ref-type="table-fn"}**4942.6**Lymphomas and leukemia54.3Pediatric high-grade CNS32.6Pediatric low-grade CNS1311.3Pediatric solid tumor32.6Pediatric leukemia/lymphoma54.3None of the above2017.4[^1][^2]

Regarding personnel safety, staff members are routinely screened for COVID-19 in 74.8% of centers, with 96.5% requiring wearing masks, face shields (80.9%), gloves (77.4%), and gowns (67%). Staggered shifts were implemented in 71.3% of facilities. Notably, 51.3% of facilities experienced personal protective equipment (PPE) shortage. Shortages in staff were mostly reported related to COVID-19 infection (27%) or family member infection (27%). New operational measures were taken, with 85.2% routinely screening all patients at the door of the facility, not allowing visitors (82.6%), and requiring patients to wear masks (82.6%). Quarantine procedures were developed for treatment of known COVID-19--positive patients at a specific daytime schedule (22.6%) or treatment at a specific vault or satellite location (10.4%).

Regarding information resources for COVID-19, 45.2% used ASTRO's COVID-19 information page and 47% used COVID-19 clinical guidance. No ASTRO-associated resources were used in 31.3% of centers.

Interestingly, 58% of responders considered whole-lung radiation therapy to carry positive effects against COVID-19 pneumonitis and would be interested in participating in a prospective trial to investigate this possibility.

All detailed answers with their corresponding absolute and percentual values are shown in [Appendix EB](#appsec1){ref-type="sec"}.

Discussion {#sec4}
==========

This is the first comprehensive effort to gather information on the impact of the COVID-19 pandemic on radiation oncology in Latin American. Despite tremendous variability in wealth and health care capacities in countries across Latin America, this survey identifies broad effects of the COVID-19 pandemic on the region's cancer care systems.

Preliminary results from the ASTRO's COVID-19 Survey, conducted among practitioners across the United States, have been lately released. Findings highlight personnel and PPE shortages, decreased patient volumes and delays in care, and significant economic impact.[@bib11] Despite supply deprivation, general preventive measures have been undertaken in practice, allowing providers to continue uninterrupted treatment delivery. However, a diminution of patient attendance is ongoing, yielding financial shrinkage.[@bib11] Based on this experience, major concern is raised for Latin American facilities. Of the consulted institutions, 50.9% are privately financed centers, which are financially highly dependent on patient influx and thus insurance reimbursement. In addition, a major deficit of PPE is affecting medical practice in the region, impairing radiation therapy services (51.3%) in the same fashion.[@bib12] Another problem arises in terms of dual practice for health care workers in the region; this might be a widely established practice, posing an additional crossed-contagion risk.[@bib13] Moreover, 27% of the consulted centers have reported personnel shortage due to COVID-19.

Determining options for not delaying treatment delivery rests mostly on the potential increased mortality risk of adopting delays. In this analysis, the sites most affected by treatment postponement were early breast cancer, PC, nonurgent palliative treatments, and nonmalignant conditions. For most, despite representing "low-risk" pathologies, unnecessary delay of treatment onset might undermine expected oncologic outcomes and miss curative possibilities for these patients.[@bib14] Options such as hypofractionation, with strong supportive data, should be explored in centers without previous experience as a potential alternative to delayed treatments.

Implementing telemedicine programs could be another beneficial strategy for follow-up schedules, as long as the patient is not required to personally attend. Compared with the US-reported 89% service offer, 64.3% in Latin America have included this feature in favor of the patients. Great advances have been achieved in the past decade in terms of remote controls, mostly through apps specially designed for these purposes; however, logistic limitations such as Internet bandwidth and socioeconomic and geographic characteristics (installed infrastructure) might affect its potential reach. Highlights from the aforementioned results can be observed in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} .Fig. 1(A) Proportion of medical practitioners per center. (B) Proportion of radiation therapists per center. (C) Experienced scarcity of resources. (D) Impact on staff attendance.Fig. 2(A) Impact on patient influx. (B) Impact on revenue. (C) Telemedicine adoption rates. (D) Current working facilities.

The novel interest for investigating whole-lung radiation therapy's effects against COVID-19 pneumonitis is another measured parameter in this survey. The willingness to participate (58%) in prospective trials to address this hypothesis should be carefully regarded. Major logistic issues in terms of preventive and protective measures might arise, endangering both practitioners and patients with cancer. Research on these grounds is encouraged only when safety criteria are met.

Conclusions {#sec5}
===========

Regional information regarding the COVID-19 pandemic in Latin America might help elucidate suitable intervention strategies for both personnel and patients. A follow-up survey will be carried out for dynamic monitoring of the pandemic's impact on radiation therapy services and adoption of ameliorating measures.

Supplementary Data {#appsec1}
==================

Appendix EA Appendix EB
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[^1]: *Abbreviations:* CNS = central nervous system; GBM = glioblastoma; GI = gastrointestinal; GYN = gynecologic; HN = head and neck; NSCLC = non-small cell lung cancer; SBRT = stereotactic body radiation therapy.

[^2]: Most frequent results.
